PE20141157A1 - Moleculas de union biespecififcas que se unen a dii4 y ang2 - Google Patents

Moleculas de union biespecififcas que se unen a dii4 y ang2

Info

Publication number
PE20141157A1
PE20141157A1 PE2013002157A PE2013002157A PE20141157A1 PE 20141157 A1 PE20141157 A1 PE 20141157A1 PE 2013002157 A PE2013002157 A PE 2013002157A PE 2013002157 A PE2013002157 A PE 2013002157A PE 20141157 A1 PE20141157 A1 PE 20141157A1
Authority
PE
Peru
Prior art keywords
dii4
ang2
join
joint component
seq
Prior art date
Application number
PE2013002157A
Other languages
English (en)
Inventor
Andreas Gschwind
Rene Georg Ott
Joachin Boucneau
Marie-Ange Buyse
Erik Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141157(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20141157A1 publication Critical patent/PE20141157A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA MOLECULA DE UNION BIESPECIFICA QUE COMPRENDE UN COMPONENTE DE UNION A ANG2, UN COMPONENTE DE UNION DII4 Y UN COMPONENTE DE UNION A ALBUMINA SERICA. DICHA MOLECULA DE UNION BIESPECIFICA, EN LA QUE LOS DOMINIOS VARIABLES INDIVIDUALES DE INMUNOGLOBULINA CONTIENEN UNA CDR3 CON UNA SECUENCIA DE AMINOACIDOS DE SEC ID N�: 1 A 166; UNA CDR1 Y CDR2 CON UNA SECUENCIA DE AMINOACIDOS CONTENIDA EN LAS SEC ID N�: 167 A 332 Y 459. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE CANCERES.
PE2013002157A 2011-04-01 2012-03-30 Moleculas de union biespecififcas que se unen a dii4 y ang2 PE20141157A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160920 2011-04-01

Publications (1)

Publication Number Publication Date
PE20141157A1 true PE20141157A1 (es) 2014-09-24

Family

ID=44314095

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002157A PE20141157A1 (es) 2011-04-01 2012-03-30 Moleculas de union biespecififcas que se unen a dii4 y ang2

Country Status (23)

Country Link
US (1) US20130078247A1 (es)
EP (1) EP2694545B1 (es)
JP (1) JP2014511682A (es)
KR (1) KR20140016345A (es)
CN (2) CN103596977B (es)
AP (1) AP2013007086A0 (es)
AR (1) AR085919A1 (es)
AU (1) AU2012234218A1 (es)
BR (1) BR112013025294A2 (es)
CA (1) CA2827809A1 (es)
CL (1) CL2013002622A1 (es)
CO (1) CO6801638A2 (es)
EA (1) EA201301109A1 (es)
EC (1) ECSP13012996A (es)
MA (1) MA35233B1 (es)
MX (1) MX337115B (es)
PE (1) PE20141157A1 (es)
PH (1) PH12013502031A1 (es)
SG (1) SG193557A1 (es)
TN (1) TN2013000389A1 (es)
TW (2) TWI551612B (es)
UY (1) UY33997A (es)
WO (1) WO2012131076A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
MX350248B (es) * 2012-03-30 2017-08-31 Boehringer Ingelheim Int Moleculas de union a ang2.
US20140093498A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
EP2900260A1 (en) * 2012-09-28 2015-08-05 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
CN106459960A (zh) 2014-05-13 2017-02-22 生物蛋白有限公司 条件活性生物蛋白
CN107540747B (zh) * 2017-08-09 2020-01-24 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12
CN110950967B (zh) * 2019-12-13 2022-05-13 山东民康生物科技有限公司 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
CN116444675B (zh) * 2023-05-11 2023-12-22 亲和(武汉)生命科技有限责任公司 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
LT2949668T (lt) * 2005-05-18 2019-11-11 Ablynx Nv Pagerinti nanokūnai tm prieš navikų nekrozės faktorių alfa
AU2006326417B2 (en) * 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
CA2654304A1 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
CN101489576A (zh) * 2006-06-06 2009-07-22 健泰科生物技术公司 用于调节血管发育的组合物和方法
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN101802015B (zh) * 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20110057244A (ko) * 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｄｌｌ4에 대한 항체 및 이의 용도
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
US20110195494A1 (en) * 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體

Also Published As

Publication number Publication date
PH12013502031A1 (en) 2013-12-16
NZ614243A (en) 2015-04-24
TW201302789A (zh) 2013-01-16
TN2013000389A1 (en) 2015-01-20
TWI551612B (zh) 2016-10-01
TWI535735B (zh) 2016-06-01
CA2827809A1 (en) 2012-10-04
UY33997A (es) 2012-09-28
ECSP13012996A (es) 2013-12-31
US20130078247A1 (en) 2013-03-28
AP2013007086A0 (en) 2013-08-31
CN106046167A (zh) 2016-10-26
CN103596977A (zh) 2014-02-19
CN103596977B (zh) 2016-07-06
EP2694545B1 (en) 2016-08-24
TW201302797A (zh) 2013-01-16
AU2012234218A1 (en) 2013-09-05
CL2013002622A1 (es) 2014-02-14
EP2694545A1 (en) 2014-02-12
MA35233B1 (fr) 2014-07-03
MX337115B (es) 2016-02-12
MX2013011032A (es) 2013-12-06
CO6801638A2 (es) 2013-11-29
EA201301109A1 (ru) 2014-08-29
WO2012131076A1 (en) 2012-10-04
BR112013025294A2 (pt) 2017-06-13
SG193557A1 (en) 2013-11-29
JP2014511682A (ja) 2014-05-19
KR20140016345A (ko) 2014-02-07
AR085919A1 (es) 2013-11-06

Similar Documents

Publication Publication Date Title
PE20141157A1 (es) Moleculas de union biespecififcas que se unen a dii4 y ang2
PE20140448A1 (es) Moleculas de union biespecificas que se unen a vegf y ang2
PE20141564A1 (es) Moleculas de union para bcma y cd3
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20131209A1 (es) Anticuerpos anti-fap
PE20141859A1 (es) Polipeptidos de union a cx3cr1
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
PE20140825A1 (es) Anticuerpos contra il-6 y sus usos
PE20190920A1 (es) Anticuerpos modificados de union a fcrn humano y metodos de utilizacion
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20090831A1 (es) Anticuerpo monoclonal
PE20141995A1 (es) Moleculas que son anticuerpos con especificidad por ox 40 humano
PE20121516A1 (es) Antidotos de anticoagulantes
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
CL2015001895A1 (es) Anticuerpos que se unen al tl1a y sus usos
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20180499A1 (es) Anticuerpos de union a tau
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
PE20140194A1 (es) Agentes de union a cd33
PE20141454A1 (es) Inmunotoxina recombinante dirigida a la mesotelina
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20140218A1 (es) Composicion farmaceutica
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20131334A1 (es) Anticuerpo igg1 humanizado

Legal Events

Date Code Title Description
FD Application declared void or lapsed